RESEARCH TRIANGLE PARK, NC--(Marketwire - June 05, 2008) - Tranzyme Pharma, a leading biopharmaceutical company that discovers and develops small molecule drugs for the treatment of gastrointestinal and metabolic diseases, announced today that Dr. Niels Ejskjaer, MD, PhD of Aarhus University Hospital, Denmark, will present Phase IIa trial results of Tranzyme's first-in-class ghrelin agonist TZP-101 at the American Diabetes Association, 68th Annual Meeting to be held in San Francisco, CA, June 6-10, 2008.
